BRISTOL-MYERS SQUIBB COMPANY Increase (Decrease) in Deferred Revenue
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Increase (Decrease) in Deferred Revenue of $3.57 billion for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2013-02-15
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for the quarter ending 2012-09-30 was $3.62B.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for the quarter ending 2012-06-30 was $43.00M.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for the quarter ending 2012-03-31 was -$91.00M.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for fiscal 2012 was $3.57B.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for fiscal 2011 was -$115.00M, a 198.29% decline from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for fiscal 2010 was $117.00M, a 13.33% decline from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY increase (decrease) in deferred revenue for fiscal 2009 was $135.00M, a 121.31% increase from fiscal 2008.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $3.62B derived: sum of 2 quarters · filed 2013-02-15 | $3.66B derived: sum of 3 quarters · filed 2013-02-15 | $3.57B 10-K · filed 2013-02-15 |
| 2012-09-30 | $3.62B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $3.66B derived: sum of 2 quarters · filed 2012-10-24 | $3.57B 10-Q · filed 2012-10-24 | $3.57B derived: sum of 4 quarters · filed 2012-10-24 |
| 2012-06-30 | $43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | -$48.00M 10-Q · filed 2012-07-25 | -$44.00M derived: sum of 3 quarters · filed 2012-07-25 | -$65.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2012-03-31 | -$91.00M 10-Q · filed 2012-04-26 | -$87.00M derived: sum of 2 quarters · filed 2012-04-26 | -$108.00M derived: sum of 3 quarters · filed 2012-04-26 | -$149.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$17.00M derived: sum of 2 quarters · filed 2012-02-17 | -$58.00M derived: sum of 3 quarters · filed 2012-07-25 | -$115.00M 10-K · filed 2012-02-17 |
| 2011-09-30 | -$21.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$62.00M derived: sum of 2 quarters · filed 2012-07-25 | -$119.00M 10-Q · filed 2011-10-27 | -$3.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-06-30 | -$41.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | -$98.00M 10-Q · filed 2012-07-25 | $18.00M derived: sum of 3 quarters · filed 2012-07-25 | $10.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-03-31 | -$57.00M 10-Q · filed 2012-04-26 | $59.00M derived: sum of 2 quarters · filed 2012-04-26 | $51.00M derived: sum of 3 quarters · filed 2012-04-26 | $25.00M derived: sum of 4 quarters · filed 2012-04-26 |
| 2010-12-31 | $116.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $108.00M derived: sum of 2 quarters · filed 2012-02-17 | $82.00M derived: sum of 3 quarters · filed 2012-02-17 | $117.00M 10-K · filed 2012-02-17 |
| 2010-09-30 | -$8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$34.00M derived: sum of 2 quarters · filed 2011-10-27 | $1.00M 10-Q · filed 2011-10-27 | $1.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | -$26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $9.00M 10-Q · filed 2011-07-28 | $9.00M derived: sum of 3 quarters · filed 2012-02-17 | $69.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $35.00M 10-Q · filed 2011-04-28 | $35.00M derived: sum of 2 quarters · filed 2012-02-17 | $95.00M derived: sum of 3 quarters · filed 2012-02-17 | $144.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $60.00M derived: sum of 2 quarters · filed 2012-02-17 | $109.00M derived: sum of 3 quarters · filed 2012-02-17 | $135.00M 10-K · filed 2012-02-17 |
| 2009-09-30 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $109.00M derived: sum of 2 quarters · filed 2010-10-26 | $135.00M 10-Q · filed 2010-10-26 | $194.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-06-30 | $49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-22 | $75.00M 10-Q · filed 2010-07-22 | $134.00M derived: sum of 3 quarters · filed 2011-02-18 | $189.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-03-31 | $26.00M 10-Q · filed 2010-04-29 | $85.00M derived: sum of 2 quarters · filed 2011-02-18 | $140.00M derived: sum of 3 quarters · filed 2011-02-18 | |
| 2008-12-31 | $59.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $114.00M derived: sum of 2 quarters · filed 2011-02-18 | $61.00M 10-K · filed 2011-02-18 | |
| 2008-09-30 | $55.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-22 | $2.00M 10-Q · filed 2009-10-22 | ||
| 2008-06-30 | -$53.00M 10-Q · filed 2009-07-23 | |||
| 2007-12-31 | $454.00M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |